Spyre Therapeutics, Inc. SYRE R2KR3KPHARMA
Company Overview
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +411.38% |
| 6 Months: | +121.62% |
| 3 Months: | +20.81% |
| 1 Month: | -13.96% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)36.48 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SYRE Spyre Therapeutics, Inc. R2KR3KPHARMA | 88.98 | -46.34 | $7.73B | 0.00% | -29.14% | -22.98% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 982.00K | 1.48M | 1.26M | 1.48M | 1.51M | 2.38M | 0 | 0 | 0 | - | - | - | - | - | - | - | 0 | 13.70M | 1.40M | 1.36M | 625.00K | 174.00K | 198.00K | 688.00K | 0 | 0 | 0 | 0 | - | - | - | - | - |
| Operating Income | -1.43M | -3.42M | -4.00M | -4.57M | -5.50M | -6.30M | -5.54M | -6.33M | -6.72M | -8.00M | -6.63M | -8.24M | -9.67M | -12.24M | -15.30M | -17.66M | -18.62M | -22.15M | -21.91M | -19.02M | -21.56M | -18.12M | -22.78M | -18.21M | -6.71M | -20.29M | -24.44M | -22.42M | -18.75M | -18.81M | -159.25M | -18.34M | -47.77M | -44.15M | -55.39M | -53.57M | -41.94M | -56.89M | -45.64M | -41.64M |
| Net Income | -1.43M | -3.41M | -3.99M | -4.55M | -5.43M | -6.24M | -5.48M | -6.25M | -6.63M | -7.87M | -6.48M | -8.12M | -9.41M | -11.92M | -14.90M | -17.17M | -18.02M | -21.57M | -21.50M | -18.73M | -21.42M | -18.03M | -22.71M | -18.22M | -6.83M | -20.31M | -24.44M | -22.32M | -18.23M | -18.42M | -217.08M | -40.11M | -43.86M | -38.84M | -69.03M | -44.77M | -36.72M | -11.18M | -69.00M | -36.20M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.10 | -0.31 | -0.37 | -0.27 | -4.84 | -4.89 | -56.79 | -9.34 | -1.20 | -0.86 | -1.36 | - | - | - | -0.74 | - |
| R&D Expense | 2.74M | 3.13M | - | 3.60M | 4.42M | 5.38M | - | 4.95M | 5.83M | 6.24M | - | 6.87M | 9.12M | 8.93M | - | 14.39M | 14.81M | 17.84M | - | 14.56M | 16.87M | 12.45M | - | 11.86M | 13.58M | 14.85M | 16.98M | 15.37M | 11.98M | 13.78M | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 4.63M | 5.21M | 3.89M | 0 | 0 | 18.74M | 2.33M | 886.00K | 0 | 0 |
| Operating Income | -8.90M | -11.31M | -21.91M | -27.68M | -45.46M | -80.33M | -81.48M | -65.65M | -84.78M | -242.30M | -208.57M | -209.56M |
| Net Income | -10.35M | -11.29M | -21.70M | -27.24M | -44.35M | -78.25M | -80.89M | -65.80M | -83.81M | -338.79M | -208.02M | -155.20M |
| Diluted EPS | - | - | - | - | - | - | -1.52 | -25.02 | -24.86 | -49.12 | - | - |
| R&D Expense | 6.83M | 11.45M | 18.14M | 22.82M | 36.72M | 64.60M | 59.64M | 57.07M | 58.58M | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 38.65M | 67.06M | 56.08M | 77.74M | 83.18M | 161.62M | 109.93M | 71.14M | 341.86M | 608.48M | 777.78M |
| Total Equity | -1.27M | -11.47M | -22.21M | 62.97M | 50.34M | 67.43M | 60.08M | 139.83M | 83.94M | 50.30M | 184.02M | 517.80M | 715.24M |
| Cash & Equivalents | 4.60M | 2.62M | 29.29M | 47.75M | 12.82M | 22.46M | 19.25M | 90.09M | 15.14M | 34.86M | 188.89M | 89.42M | 85.72M |
| Total Liabilities | - | - | 2.55M | 4.10M | 5.74M | 10.31M | 23.10M | 21.79M | 25.98M | 20.84M | 73.29M | 90.68M | 62.55M |
| Current Liabilities | - | - | 2.52M | 3.96M | 5.63M | 10.24M | 18.36M | 16.44M | 20.14M | 14.66M | 31.98M | 54.06M | 58.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -18.84M | -24.61M | -32.19M | -65.69M | -75.78M | -53.72M | -80.14M | -99.91M | -157.41M | -169.25M |
| Investing Cash Flow | - | - | -12.08M | -22.53M | -15.23M | -1.74M | -7.60M | -22.62M | 57.01M | -108.39M | -353.29M | -143.47M |
| Financing Cash Flow | - | - | 49.37M | 12.21M | 57.07M | 65.72M | 154.51M | 1.39M | 42.68M | 361.08M | 410.91M | 309.02M |
| Capital Expenditure | -181.00K | -208.00K | -212.00K | -619.00K | -422.00K | -1.49M | -4.28M | -573.00K | -38.00K | -0 | -0 | - |
| Free Cash Flow | - | - | -19.05M | -25.23M | -32.62M | -67.18M | -80.06M | -54.29M | -80.18M | -99.91M | -157.41M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -473.3% | -531.7% | -1,169.3% | - | - | -350.3% | -3,640.2% | -27,348.0% | - | - |
| Net Margin % | - | - | -468.8% | -523.3% | -1,140.6% | - | - | -351.1% | -3,598.8% | -38,238.1% | - | - |
| ROE % | 90.2% | 50.9% | -34.5% | -54.1% | -65.8% | -130.2% | -57.9% | -78.4% | -166.6% | -184.1% | -40.2% | -21.7% |
| ROCE % | - | -31.3% | -34.7% | -54.9% | -67.4% | -123.9% | -56.1% | -73.1% | -150.1% | -78.2% | -37.6% | -29.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.81% | 13.03M | $1.18B |
| 2 | Blackrock Inc. | 7.40% | 6.51M | $587.94M |
| 3 | Perceptive Advisors Llc | 4.91% | 4.32M | $390.31M |
| 4 | RTW Investments LP | 4.84% | 4.25M | $384.21M |
| 5 | Paradigm Biocapital Advisors LP | 4.37% | 3.84M | $347.05M |
| 6 | Vanguard Capital Management LLC | 3.92% | 3.45M | $311.62M |
| 7 | State Street Corporation | 3.48% | 3.06M | $276.27M |
| 8 | Venrock Adviser, LLC | 3.40% | 2.99M | $269.77M |
| 9 | Price (T.Rowe) Associates Inc | 3.37% | 2.96M | $267.54M |
| 10 | Driehaus Capital Management, LLC | 3.18% | 2.80M | $252.93M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SYRE
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQUm5sQ2Nsdlo0VElobTdrMzdzcFdybFlZam9XZnhocEhoUkpGSEVVeFhGMVJrVEl1cnR4VHlDOFdmeHI2bEJKVnBoMFZ6S0lCMHRjdnRLR0JjR3YxR2s0Z1VFTk5sRkRPbWt1MlRWWnVEeXRRU0p3V0xITDdqelEzR29FbnAyclRKWm93MX…
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNOEVIeXowRzJsWVd1RUFJNzFGNlFiaHhxWWhpOGZ1RG1XZy1VcVJfNUhlc25FWi1HLV9iZjdtWXVseW5iWWZXRzQtUmoxaV9BYkV6d2FpcDM1Smt5ZFpFWGU2MGIwMzJGQVFqa2QxMGdIeXM3TFI4VmRNM2gtb20tNklsYW9VR25VWHJnWn…
Insider Sale: See Remarks of $SYRE Sells 400 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOWDNhVFc4MUdJRkJ4emxUaWJSUHQ0MlZqaWc4dS1DZVpfdjFLbHNjaks2YzUtdjNCakFXVHFiYjIxOGNaOFQyd1pOMERJMUlfU2kyTmlVSG5NM0J3c0VJcG05dThmQkxTRm1sS1BiSE5tNzBfRVpkS3kteDAzcEk1VzZaUHVyUHBmLVN1eU…
Spyre Therapeutics (SYRE) Reports RA Trial Results, Is The Stock Overvalued? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOV2lIaEtLVjJ3eHJ4bHRIT05jdVFyblh0TnQzanlYcUlzMTgyY0ZQaUJianRHdGRSdTN1REhPWEhvTDc2Qm9Ta1J6d1pVWHNBMXFDbjhUYlNhUU9PelB6ZUwycWEwaWxLWjktaEF2Q0ctRzhvaWJMd2drMzVvUXZPVF9ZMWd6UFhGcEtDcV…
Spyre Therapeutics (SYRE) CFO sells over 25K shares in planned trades - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOTllLNHM2WFIxQ2ktMEVWNmxPTTNzUWRYTGgyWDlkWUp2X2FGa1dOck82c3V0eTFjTThmSkk1UTE3UHBSaGY0TUVkdlhoMGF0M3RpSDBHNjVOeWdvTXNpcV9BNUZuLXFwYTFacGZSWC1uZHRDMVBubUQtWW1iLVRhd3k0VVB4eWhESnZwTm…
The Technical Signals Behind (SYRE) That Institutions Follow - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQQk12ZnVkOVhlMXVfQUU2aW9vZmtXNXpHUFVQOHV0SnBRVlBqdWhBcUYxdXNnQjJBc3FhNXlUQTdBZldkTDF5S0xtdEtoMGVBak81dG9JMm1taDVyMU1Bcm1CeVZqcnVxZ3BaVjJubGYxNW1oQWpjdlNXcTA5N0N6b1d0OWNuT3IzVk02eU…
SYRE — Frequently Asked Questions
What is the current share price of Spyre Therapeutics, Inc. (SYRE)?
As of 2026-09-07 16:24 PDT, Spyre Therapeutics, Inc. (SYRE) trades at $88.98 on NasdaqGS. Its 52-week range is $14.82 to $108.92.
What is the market capitalisation of SYRE?
Spyre Therapeutics, Inc. (SYRE) has a market capitalisation of $7.73B on NasdaqGS.
What is the P/E ratio of SYRE?
SYRE trades at a trailing price-to-earnings (P/E) ratio of -46.34. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 9.68.
What is the return on equity (ROE) of SYRE?
SYRE has a return on equity (ROE) of -22.98%. Its return on capital employed (ROCE) is -29.14%.
Is SYRE a good stock to buy?
This page provides a data-driven analysis of Spyre Therapeutics, Inc. (SYRE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.